Laura Yecies is an accomplished leader in medical technology, dedicated to transforming healthcare through innovation. As CEO of Osteoboost Health, Inc., she is tackling the global low bone density epidemic with the new Osteoboost precision vibration therapy device, the first medical device approved by the FDA to treat osteopenia.

A seasoned executive with a track record of scaling disruptive technologies, Ms. Yecies has led multiple high-growth companies, including NeuroSync, Catch (acquired by Apple), and SugarSync (acquired by J2Global). Earlier in her career, she played a pivotal role in shaping the digital landscape, leading the Browser division at Netscape, Yahoo’s Mail, and global marketing at cybersecurity giant Check Point.

With a legacy spanning product development, commercialization, and market leadership, Ms. Yecies has driven innovations that have improved the lives of over 350 million users worldwide. She holds an MBA from Harvard, an MSFS from Georgetown, and an AB in Government, magna cum laude, from Dartmouth. A sought-after speaker, podcaster, and writer on healthcare and technology, Ms. Yecies has been profiled in The New York Times, Forbes, and numerous industry publications.

Ms. Yecies has served on the boards of several community non-profits, volunteered in the U.S. State Department TechWomen program, and volunteered as a translator with medical teams in Guatemala (she speaks Portuguese, Spanish, and French).

Osteoboost is the first and only FDA-approved non-pharmacological prescription treatment for low bone density with an addressable market of $30 billion for the 64 million patients with osteopenia (and osteoporosis). Osteoboost puts NASA vibration technology into a wearable class 2 prescription medical device – a convenient belt, focusing the vibration on the hips and lumbar spine. In a gold-standard randomized controlled trial, Osteoboost reduced loss of vertebral bone strength and bone density by over 83%. Osteoboost is building the first comprehensive solution for bone strength and includes the recently acquired Wellen osteoporosis exercise program - personalized training to reduce fall risk. The Osteoboost Digital Care Program provides a comprehensive therapeutic intervention of patient care allowing for reimbursement via RTM. Osteoboost has achieved over $1 million in early sales and 1,400 prescribing physicians, including more than 30 leading academic institutions. Osteoboost achieved a De Novo approval and Breakthrough Device status from the FDA and $4.7 million in NIH grants.